仟源医药: 关于2024年限制性股票激励计划第一个解除限售期解除限售股份上市流通提示性公告

Core Points - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has successfully achieved the conditions for the first unlock period of its 2024 Restricted Stock Incentive Plan [1][5] - The first unlock period allows for the release of 40% of the granted restricted stocks, which were awarded on June 3, 2024, and the unlock date is set for July 25, 2025 [5][6] - The company has completed the necessary approval procedures and has publicly disclosed the list of incentive objects [2][3] Summary by Sections Incentive Plan Approval - The board of directors approved the first unlock conditions at the 29th meeting of the fifth board on July 17, 2025 [1] - The plan has undergone all required approval processes, including the authorization from the shareholders' meeting [2] Unlock Conditions Achievement - The company has met all conditions for the first unlock period, including no adverse audit opinions and compliance with performance assessment requirements [5][6] - The performance targets for the first unlock period include achieving a revenue growth rate and a net profit growth rate compared to the previous year [6][7] Specifics of the Unlock - A total of 705,000 shares were granted to 50 incentive objects, with 40% eligible for release during this period [3][5] - The total number of shares eligible for release represents 1.08% of the company's total share capital of 248,318,563 shares [9][10] - The company has also noted that three incentive objects have left the company, resulting in the repurchase and cancellation of 350,000 shares [8][9]